Wegovy vs Zepbound: An Honest, Evidence-Based Comparison

Wegovy and Zepbound are the two leading weight-management GLP-1 medications, and “which is better?” is one of the most-searched questions in the category. The honest answer: Zepbound produced larger average weight loss in the trials, but averages aren’t individuals, and the right choice depends on your body, tolerance, coverage, and access. Here’s the evidence, laid out fairly.

This is educational information, not medical advice or a recommendation. The choice between these medications is one to make with your prescriber.

The basics

The headline mechanistic difference: Wegovy targets one gut-hormone receptor; Zepbound targets two. That second target (GIP) is the leading explanation for the difference in results.

Average weight loss: what the trials show

• Wegovy — in STEP 1, average ~15% of body weight lost over 68 weeks at 2.4 mg.
• Zepbound — in SURMOUNT-1, average ~21% over 72 weeks at 15 mg (and ~15% even at the 5 mg dose).
• Head-to-head — SURMOUNT-5 (2025) compared them directly and found greater average weight loss with tirzepatide than semaglutide 2.4 mg.

So on the trial averages, Zepbound comes out ahead. But note the word average: response to each molecule varies substantially between people, and plenty do excellently on Wegovy. The trials describe populations, not your individual outcome.

Side effects

The profiles are broadly similar — mostly gastrointestinal (nausea, diarrhea, constipation, vomiting), mostly during titration, mostly mild to moderate. Both carry the same class warnings, including the thyroid boxed warning and pancreatitis caution. There’s no clear “gentler” option across the board — individual tolerance differs, and some people genuinely do better on one than the other.

Dosing and titration

Both start low and climb every ~4 weeks:

• Wegovy: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg.
• Zepbound: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg.

Zepbound’s extra steps give more room to find a maintenance dose that balances results and side effects.

Cost, coverage, and access

This is often the real deciding factor, and it changes constantly:

• Insurance coverage varies by plan for both — many plans cover one, the other, or neither for weight (see getting covered).
• Savings cards and cash-pay options exist from both manufacturers, with evolving terms.
• Supply has affected both at various times.

For many people, “which does your insurance cover, and what can you actually get?” settles the question before efficacy does.

So which should you choose?

There’s no universal winner. A reasonable way to think about it:

• Trial data favors Zepbound on average weight loss.
• Individual response, tolerance, coverage, and availability can easily point the other way for you.
• Switching later is common and possible (see switching medications) if the first choice underperforms or isn’t tolerated.

The productive move is to bring this evidence to your prescriber and decide together — then track your actual response, because your own weight trend and side-effect pattern on the drug you choose is the only data that’s truly about you.

Sources: STEP 1 (Wilding et al., NEJM 2021); SURMOUNT-1 (Jastreboff et al., NEJM 2022); SURMOUNT-5 head-to-head (2025); Wegovy and Zepbound prescribing information.